Gilead Sciences Inc (GILD) 80.46 $GILD What Awaits MNK &

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Gilead Sciences Inc (GILD) 80.46 $GILD

What Awaits MNK & Other Drug Stocks this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:00AM CDT
Let's see what's in store for some medical companies that are expected to declare quarterly numbers on Aug 2.
MNK: 67.37 (+0.03), BIIB: 301.83 (+11.90), ABT: 45.29 (+0.54), JNJ: 125.40 (+0.17), GILD: 80.46 (+0.99), MRK: 58.66 (unch), PFE: 37.31 (+0.42), SGNT: 21.68 (-0.01), ABBV: 66.94 (+0.71), PRTA: 56.66 (+1.61), NVS: 83.07 (-0.19)

Gilead Sciences (GILD) Approaches New Downside Target of $79.92
Comtex SmarTrend(R) - Fri Jul 29, 9:09AM CDT
Gilead Sciences (NASDAQ:GILD) has opened bearishly below the pivot of $81.28 today and has reached the first level of support at $80.58. Should the shares continue to fall, the support pivots of $79.92 and $78.56 will be of interest.
GILD: 80.46 (+0.99)

What Awaits ACUR & Other Drug Stocks this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:43AM CDT
Medical is one of the six sectors that are projected to record positive earnings growth this quarter.
ABT: 45.29 (+0.54), JNJ: 125.40 (+0.17), GILD: 80.46 (+0.99), NVLS: 4.76 (+0.08), CYTR: 0.60 (-0.05), CEMP: 18.50 (+0.53), ACUR: 1.91 (-0.03), NVS: 83.07 (-0.19)

Research Reports for Facebook, DuPont, Gilead & Others
Sheraz Mian - Zacks Investment Research - Thu Jul 28, 1:23PM CDT
Research Reports for Facebook, DuPont, Gilead & Others
GS: 158.18 (-0.63), GILD: 80.46 (+0.99), FB: 124.31 (+0.37), BCE: 48.02 (+0.13), ADI: 63.98 (+0.15), DD: 69.35 (+0.18), M: 35.32 (-0.51)

The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Amgen and Celgene
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Amgen and Celgene
BIIB: 301.83 (+11.90), GILD: 80.46 (+0.99), AMGN: 174.16 (+2.13), ABBV: 66.94 (+0.71), CELG: 114.69 (+2.50)

2 Large Cap Drug Stocks to Watch for Earnings: ABBV & MRK
Arpita Dutt - Zacks Investment Research - Thu Jul 28, 5:47AM CDT
Two major large cap drug stocks, AbbVie (ABBV) and Merck (MRK) will be reporting second quarter results tomorrow.
BIIB: 301.83 (+11.90), JNJ: 125.40 (+0.17), GILD: 80.46 (+0.99), MRK: 58.66 (unch), AMGN: 174.16 (+2.13), ABBV: 66.94 (+0.71)

Biotech Stock Roundup: Biogen Q2 Results Impress, Gilead HCV Franchise Under Pressure
Arpita Dutt - Zacks Investment Research - Wed Jul 27, 2:25PM CDT
With the second quarter earnings season in full swing, several biotech companies including Amgen (AMGN) will be reporting this week.
BIIB: 301.83 (+11.90), VRTX: 98.20 (+1.20), GILD: 80.46 (+0.99), ALXN: 133.50 (+4.90), AMGN: 174.16 (+2.13), ABBV: 66.94 (+0.71), CELG: 114.69 (+2.50)

Express Scripts (ESRX) Posts In-Line Earnings, Lags Revenues (Revised)
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 10:19AM CDT
Pharmacy benefit manager Express Scripts Holding Company (ESRX) posted second-quarter 2016 earnings per share (excluding special items) of $1.57, in line with the Zacks Consensus Estimate.
ANTM: 127.61 (-3.73), JNJ: 125.40 (+0.17), ESRX: 76.17 (+0.10), GILD: 80.46 (+0.99)

Watch for Drug Stocks Earnings on Jul 28: BMY, CELG & More
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 8:47AM CDT
How will drug stocks Bristol-Myers, Celgene and others perform when they report Q2 results on Jul 28, before the opening bell?
AGEN: 5.65 (+0.10), BIIB: 301.83 (+11.90), ABT: 45.29 (+0.54), JNJ: 125.40 (+0.17), GILD: 80.46 (+0.99), ALXN: 133.50 (+4.90), ARIA: 9.71 (+0.20), BMY: 76.19 (+1.38), CELG: 114.69 (+2.50), NVS: 83.07 (-0.19)

Gilead Sciences Inc A Great Opportunity Post Q2 Earnings
Jack Foley - Amigobulls - Wed Jul 27, 6:47AM CDT
Gilead Sciences Inc (NASDAQ:GILD) shares tumbled after the company reported its Q2 earnings. Here's why this could be a great opportunity for investors.
GILD: 80.46 (+0.99)

Downgrade Alert for Gilead Sciences (GILD)
Comtex SmarTrend(R) - Wed Jul 27, 4:11AM CDT
Gilead Sciences (NASDAQ:GILD) was downgraded from Buy to Hold at Needham today. The stock closed yesterday at $81.05 on volume of 47.3 million shares, above average daily volume of 11.2 million. There is potential upside of 55.2% for shares of Gilead Sciences based on a current price of $81.05 and an average consensus analyst price target of $125.80. The stock should find initial resistance at its 50-day moving average (MA) of $92.98 and further resistance at its 200-day MA of $100.22.
GILD: 80.46 (+0.99)

After GILD Earnings, Which Biomed Stock is Best Right Now?
Ryan McQueeney - Zacks Investment Research - Tue Jul 26, 3:55PM CDT
For many investors, Gilead is the go-to stock in the biomed industry. However, with revenues looking sluggish this year, these three Zacks Rank #1 (Strong Buy) stocks might end up being a better bet.
INVA: 13.04 (+0.17), GILD: 80.46 (+0.99), ANIP: 61.06 (+0.46)

Gilead Sciences and McDonald's slip; Texas Instruments rises
AP - Tue Jul 26, 3:32PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Tuesday:
CNC: 69.44 (-1.11), CE: 62.88 (-0.54), GILD: 80.46 (+0.99), TXN: 69.88 (+0.13), LVS: 50.24 (-0.41), SIRI: 4.34 (-0.05)

SmarTrend Watching for Potential Rebound in Shares of Gilead Sciences After 8.45% Loss
Comtex SmarTrend(R) - Tue Jul 26, 11:45AM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $81.02 to a high of $84.15. Yesterday, the shares fell 8.4%, which took the trading range below the 3-day low of $86.28 on volume of 29.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GILD: 80.46 (+0.99)

Gilead Sciences Set to Possibly Rebound After Yesterday's Selloff of 8.45%
Comtex SmarTrend(R) - Tue Jul 26, 11:43AM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $81.02 to a high of $84.15. Yesterday, the shares fell 8.4%, which took the trading range below the 3-day low of $86.28 on volume of 29.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GILD: 80.46 (+0.99)

Gilead (GILD) Beats on Q2 Earnings, Cuts 2016 Sales View
Zacks Equity Research - Zacks Investment Research - Tue Jul 26, 9:07AM CDT
Gilead Sciences' (GILD) second-quarter 2016 earnings beat the Zacks Consensus Estimate by a penny while revenues missed estimates; product sales outlook is lowered.
INVA: 13.04 (+0.17), FCSC: 1.02 (-0.07), GILD: 80.46 (+0.99), NKTR: 17.76 (+0.47)

The Zacks Analyst Blog Highlights: Texas Instruments, Gilead Sciences and Las Vegas Sands
Zacks Equity Research - Zacks Investment Research - Tue Jul 26, 8:30AM CDT
The Zacks Analyst Blog Highlights: Texas Instruments, Gilead Sciences and Las Vegas Sands
GILD: 80.46 (+0.99), TXN: 69.88 (+0.13), LVS: 50.24 (-0.41)

Express Scripts (ESRX) Tops Q2 Earnings, Lags Revenues
Zacks Equity Research - Zacks Investment Research - Tue Jul 26, 7:55AM CDT
Pharmacy benefit manager Express Scripts Holding Company (ESRX) posted second-quarter 2016 earnings per share (excluding special items) of $1.57, in line with the Zacks Consensus Estimate.
ANTM: 127.61 (-3.73), JNJ: 125.40 (+0.17), ESRX: 76.17 (+0.10), GILD: 80.46 (+0.99)

Roche (RHHBY) Misses on Q2 Revenues, New Launches in Focus
Zacks Equity Research - Zacks Investment Research - Mon Jul 25, 5:32PM CDT
Roche Holding (RHHBY) reported sales of $12.1 billion in the second quarter of 2016, missing the Zacks Consensus Estimate of $12.9 billion.
JNJ: 125.40 (+0.17), GILD: 80.46 (+0.99), ABBV: 66.94 (+0.71)

Q2 Earnings After the Bell Monday: TXN, GILD, LVS
Mark Vickery - Zacks Investment Research - Mon Jul 25, 4:49PM CDT
Texas Instruments, Gilead Sciences and Las Vegas Sands are among the smorgasbord of Q2 earnings reports today.
GILD: 80.46 (+0.99), TXN: 69.88 (+0.13), LVS: 50.24 (-0.41)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LEPAS AURA Signals a Sharper Design Bet for Future Cars

Updated Category News Views 145

A porcelain-smooth concept car is not a balance sheet, but it can tell you where a young automotive brand intends to spend its attention. LEPAS unveiled AURA in October at its first Global Elegant Lifestyle Week, presenting it as the brand's first global concept car and a fresh expression of its Leopard Aesthetics design language. That matters because AURA is plainly not...

Continue Reading
Valley Family Health Breach Notice Raises Hard Questions

Updated Category News Views 41

Seven months is a long time for sensitive patient data to sit inside an unresolved security story. Valley Family Health Care, Inc. says it suffered a network disruption on or about March 13, 2026, investigated with outside cybersecurity specialists, and ultimately determined that an unauthorized actor accessed and acquired certain files. The formal notification process...

Continue Reading
Chemours Legal Succession Gets a Long Transition Runway

Updated Category News Views 46

A corporate-law handoff rarely sets pulses racing, but this one deserves a proper look. Chemours is replacing its long-serving general counsel while keeping the departing executive in the building for four additional months. That is not flashy, and thank goodness for that. In a global chemicals company, legal leadership touches regulation, compliance, governance,...

Continue Reading
Peptide Labels Cannot Substitute for Clinical Care

Updated Category News Views 91

A Label Is Not a Care Plan Those three little words, research use only, carry far more weight than a flashy product page would have people believe. The HelloNation article featuring wellness expert Andres Giraldo makes a plain but necessary distinction: a research-use-only, or RUO, label does not turn a peptide into prescribed treatment, and it sure does not establish...

Continue Reading
Visual Cipher Bench Exposes AI Agents' Hidden Rule Gap

Updated Category News Views 95

Forty little black-and-white puzzles just threw a bucket of cold water on the autonomous-agent sales pitch. Einsia AI’s Navers Lab says its new Visual Cipher Bench found that the best result among eight frontier models was only 26.7%, with no tested configuration clearing 30%. That is not a minor blemish. It is a reminder that a model can sound clever, use tools, and...

Continue Reading
SAGA's Radar Assays Tighten the Trapper North Case

Updated Category News Views 125

Rock that keeps showing up where the model says it should is the sort of boring news a junior miner desperately needs. SAGA Metals has put out fresh assay results from Radar’s Trapper North area, and the useful part is not merely a loud grade in one hole. It is the apparent persistence of thick titanium-vanadium-iron oxide mineralization across tighter-spaced drilling....

Continue Reading
Excel Treatment Center Adds ART Trauma Therapy Option

Updated Category News Views 117

Trauma rarely arrives at an addiction program wearing a name tag. Excel Treatment Center in Dover, New Jersey, is responding to that uncomfortable reality by adding Accelerated Resolution Therapy® (ART) to the individual, group, and family therapy already available to its clients. The center says its therapists have completed ART training, and the approach is now part of...

Continue Reading
BKV Energy's $400,000 Loyalty Bet Has a Real Point Behind It

Updated Category News Views 73

Retail power customers rarely send thank-you notes; they switch plans, complain about bills, or quietly vanish. That is why BKV Energy putting more than $400,000 into its third annual ElectroShare payout deserves a harder look than the usual feel-good loyalty announcement. A Retention Expense With Some Teeth The payout has climbed quickly: roughly $113,000 in the first...

Continue Reading
MERSCO’s Holiday Push Tests Backyard Play Demand in 2026

Updated Category News Views 22

A trampoline sale is not exactly a macroeconomic bellwether, but it does expose a useful little corner of holiday spending: parents buying big, awkward, discretionary stuff that has to earn its space in the yard. MERSCO is joining Amazon’s Black Friday and Cyber Monday window from November 19 through November 30, 2026, with discounts reaching 38% on selected products....

Continue Reading
Elijah Craig Uses AI Toasts to Sell a Warmer Pour

Updated Category News Views 38

A Speech Prompt With a Bourbon Label Few things expose holiday nerves faster than a raised glass and a room waiting for somebody to say something memorable. Elijah Craig has decided that awkward little moment is marketing territory, rolling out its Digital Perfect Pour, Perfect Toast Generator for mobile and desktop users ahead of the holiday season. The tool asks for a...

Continue Reading
/section>

Top 5 Most Recently Viewed Articles

Unveiling Groundbreaking Research on Cenobamate at AES 2025

Updated Category News Views 163

Exciting New Developments in Epilepsy Treatment SK Life Science, Inc., a leading player in central nervous system (CNS) disorder treatments and a subsidiary of SK Biopharmaceuticals Co., Ltd., is ready to unveil ten posters featuring new research on cenobamate at the upcoming American Epilepsy Society (AES) Annual Meeting. This prestigious event will take place in...

Continue Reading
Teck Resources Unveils Strong First Quarter Earnings for 2025

Updated Category News Views 384

Teck Resources Limited Reports Impressive First Quarter Results Teck Resources Limited (NYSE: TECK, TSX: TECK.A, TSX: TECK.B) has announced its unaudited financial results for the first quarter of 2025, showcasing significant improvements over previous years. This marks a period of enhanced profitability driven by favorable market conditions. Financial Performance...

Continue Reading
Understanding Your Rights in the Symbotic Class Action

Updated Category News Views 155

Taking Action: Your Rights as an Investor in Symbotic Inc. Investors of Symbotic Inc. should be aware of a class action lawsuit initiated on their behalf. The law firm Kirby McInerney LLP is advocating for those who acquired Symbotic securities during the noted class period. This comes as a crucial reminder for shareholders to stay informed and consider their rights in...

Continue Reading
Scott Kelly Joins Worthington Steel Board, Boosting Strategy

Updated Category News Views 431

Scott Kelly Named to Worthington Steel Board Worthington Steel, Inc. (NYSE:WS), a prominent player in the metals processing industry, has officially welcomed Scott Kelly to its board of directors. This strategic appointment comes at a significant time as the company navigates its market challenges, including a recent 10% dip in stock price. Despite this, Worthington...

Continue Reading
Treasury Securities Agreements: A New Era for Primary Dealers

Updated Category News Views 232

Understanding the Latest Developments in Treasury Securities In a significant move to fortify the issuance and market making in Treasury securities, the Government Debt Management, on behalf of the Treasury, has signed crucial agreements with primary dealers. This initiative aims to ensure the Treasury’s uninterrupted access to financing while enhancing price formation...

Continue Reading